Additionally, APOB inhibition decreased the risk of lung cancer in ever-smokers via LDL (OR 0.82, 95% CI 0.71–0.96, p = 0.040) and TG (OR 0.62, 95% CI 0.46–0.83, p = 0.015) reduction by 1 SD. Here, APOB is linked to lung cancer.